Rapid drug discovery is a pressing need in the pharmaceutical industry. As new target
proteins are proposed for therapeutic intervention, the methods of random screening or
rational drug design may not be adequate to the challenge. SELEX1-derived
oligonucleotides, possessing shapes that interact with target molecules, may provide a
surprising alternative to other ligand discovery technologies. In addition, the technology
leads to a novel research idea that may enrich our understanding of the mechanisms by …